- Cigna Corporation's (NYSE: NYSE:) Q3 sales increased 2.4% to $45.3 billion, beating the consensus of $44.76 billion. Adjusted revenues were $45.4 billion, reflecting strong performance led by Evernorth.
- Quarterly sales at Cigna's Evernorth unit rose about 6% to $35.70 billion, driven by strong growth in its specialty pharmacy services.
- Growth in Evernorth drove revenue growth, while its insurance business managed to keep tight control on costs.
- The medical care ratio, a measure of medical expenses against premiums collected, improved to 80.8% from 83.5% a year ago when there was a surge in COVID cases.
- Total insurance customers rose 5.6% to nearly 18 million as an increase in commercial insurance memberships softened the blow from a decline in government-backed plans.
- Guidance: Cigna now expects adjusted income from operations of at least $23.10 per share compared with a prior forecast of at least $22.90 per share. Analysts expect a full-year profit of $23 per share.
- It projects FY22 revenues of at least $179 billion (at least $178 billion expected earlier)
- For FY22, the company expects total Medical Customer Growth (lives) of at least 900,000, up from the 800,000 anticipated earlier.
- Price Action: CI shares are up 1.39% at $325.31 on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Read the original article on Benzinga
